| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/06/2011 | EP2305709A1 Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof |
| 04/06/2011 | EP2305708A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 04/06/2011 | EP2305707A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 04/06/2011 | EP2305706A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 04/06/2011 | EP2305699A1 Stabilised mRNA with increased G/C content which is optimised for translation in its coded areas |
| 04/06/2011 | EP2305698A2 Macrocyclic inhibitors of Hepatitis C virus replication |
| 04/06/2011 | EP2305697A2 Macrocyclic inhibitors of Hepatitis C virus replication |
| 04/06/2011 | EP2305696A2 Macrocyclic inhibitors of Hepatitis C virus replication |
| 04/06/2011 | EP2305695A2 Macrocyclic inhibitors of Hepatitis C virus replication |
| 04/06/2011 | EP2305353A1 Augmented cognitive training |
| 04/06/2011 | EP2305315A1 Method for in vivo regulation of cardiac muscle contractility |
| 04/06/2011 | EP2305314A2 Remodelling and glycoconjugation of antibodies |
| 04/06/2011 | EP2305313A2 Remodelling and glycoconjugation of interferon-alpha (IFNa) |
| 04/06/2011 | EP2305312A2 Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) |
| 04/06/2011 | EP2305311A2 Glycoconjugation of peptides |
| 04/06/2011 | EP2305305A1 Agent for induction/maintenance of remission |
| 04/06/2011 | EP2305304A1 Immunopotentiating agent comprising ep1 agonist |
| 04/06/2011 | EP2305302A2 Prevention and treatment of amyloidogenic disease |
| 04/06/2011 | EP2305301A2 Methods of diagnosing and treating pre-eclampsia or eclampsia |
| 04/06/2011 | EP2305300A1 Pharmaceutical composition for treatment and prevention of cancer |
| 04/06/2011 | EP2305299A1 Chimeric alphavirus replicon particles |
| 04/06/2011 | EP2305291A1 Use of proteasome inhibitors for the treatment of HIV infections |
| 04/06/2011 | EP2305290A1 Salt-free composition comprising an intact Botulinum toxin complex |
| 04/06/2011 | EP2305289A1 Medicinal products for the treatment of blood coagulation disorders |
| 04/06/2011 | EP2305288A2 Acidic insulin preparations with improved stability |
| 04/06/2011 | EP2305287A1 Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| 04/06/2011 | EP2305286A2 Treatment for Alzeimer's disease |
| 04/06/2011 | EP2305285A1 Means and methods for treating ischemic conditions |
| 04/06/2011 | EP2305284A2 Use of EGFR transactivation inhibitors in human cancer |
| 04/06/2011 | EP2305283A1 Pharmaceutical compositions for treating dysregulated inflammatory diseases |
| 04/06/2011 | EP2305282A2 Prevention and treatment of amyloidogenic disease |
| 04/06/2011 | EP2305276A2 Processed lipoaspirate cells for use in therapy |
| 04/06/2011 | EP2305258A2 Inhibition of neuronal damage |
| 04/06/2011 | EP2305251A2 Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder |
| 04/06/2011 | EP2305242A2 20-carboxy-(S)-trioxilin A3 for treating neurologic disorders |
| 04/06/2011 | EP2305221A1 Dna damage repair inhibitors for treatment of cancer |
| 04/06/2011 | EP2305220A2 Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| 04/06/2011 | EP2305213A2 The treatment of small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| 04/06/2011 | EP2304438A1 Assessment of complications of patients with type 1 diabetes |
| 04/06/2011 | EP2304431A1 Csf biomarkers for the prediction of cognitive decline in alzheimer's disease patients |
| 04/06/2011 | EP2304049A1 Method of treatment of vascular complications |
| 04/06/2011 | EP2304046A1 Factor viii muteins with reduced immunogenicity |
| 04/06/2011 | EP2303921A2 Mutated netrin-4 proteins, fragments thereof and their uses as drugs |
| 04/06/2011 | EP2303920A2 AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES |
| 04/06/2011 | EP2303918A2 Methods for dosing an activin-actriia antagonist and monitoring of treated patients |
| 04/06/2011 | EP2303917A2 Antagonists of actriib and uses for increasing red blood cell levels |
| 04/06/2011 | EP2303916A1 Method for producing intermediates for the production of novel macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof, and uses of said macrocycles |
| 04/06/2011 | EP2303915A2 Pseudacyclin and method of indication of a fungus pseudallescheria boydii |
| 04/06/2011 | EP2303913A2 Crkl targeting peptides |
| 04/06/2011 | EP2303912A1 Cdca1 epitope peptides and vaccines containing the same |
| 04/06/2011 | EP2303910A1 Multi-leu peptides and analogues thereof as selective pace4 inhibitors and effective antiproliferative agents |
| 04/06/2011 | EP2303407A1 Methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells |
| 04/06/2011 | EP2303335A1 Method of treating hearing loss using xiap |
| 04/06/2011 | EP2303326A2 Treatment of solid tumors with tissue inhibitors of metalloproteinases (timps) |
| 04/06/2011 | EP2303314A1 Chloramphenicol acetyl transferase (cat)-defective somatostatin fusion protein and uses thereof |
| 04/06/2011 | EP2303313A2 Exendins to lower cholestrol and triglycerides |
| 04/06/2011 | EP2303312A2 Smallpox dna vaccine and the antigens therein that elicit an immune response |
| 04/06/2011 | EP2303311A1 Use of angiogenin or angiogenin agonists for treating diseases and disorders |
| 04/06/2011 | EP2303310A2 Compositions and methods for using cells to treat heart tissue |
| 04/06/2011 | EP2303309A2 Treatment of mitochondrial diseases with an erythropoietin mimetic |
| 04/06/2011 | EP2303308A2 Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis |
| 04/06/2011 | EP2303307A2 Recombinant preparation of bromelain inhibitors and bromelain inhibitor precursor |
| 04/06/2011 | EP2303306A2 Development of a c-reactive protein mutant with improved therapeutic benefit in immune thrombocytopenia and lupus nephritis |
| 04/06/2011 | EP2303305A2 Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling |
| 04/06/2011 | EP2303304A1 Methods of treating cancer with apoe peptides |
| 04/06/2011 | EP2303303A2 Methods of effecting wnt signaling through dkk structural analysis |
| 04/06/2011 | EP2303296A2 Orally administerable vaccine for yersinia pestis |
| 04/06/2011 | EP2303268A1 Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and their use |
| 04/06/2011 | EP2303247A2 Transdermal system for extended delivery of incretins and incretin mimetic peptides |
| 04/06/2011 | EP2303237A2 Preparation method of biodegradable micro-particles containing drugs |
| 04/06/2011 | EP2303226A2 Sustained delivery of exenatide and other polypeptides |
| 04/06/2011 | EP2303033A2 Particles of collagen material and process for the preparation |
| 04/06/2011 | EP2303011A2 Vegf165 delivered by fibrin sealant to reduce tissue necrosis |
| 04/06/2011 | EP2091513B1 Ejection liquid and ejection method |
| 04/06/2011 | EP1848414B1 Method for treating gefitinib resistant cancer |
| 04/06/2011 | EP1841781B1 Il-22 for use in the treatment of obesity, diabetes, hyperlipidemia, hyperglycemia and hyperinsulinemia |
| 04/06/2011 | EP1721157B1 Use of antibodies to tweak for the treatment of stroke |
| 04/06/2011 | EP1594889B1 Nell peptide expression systems and bone formation activity of nell peptide |
| 04/06/2011 | EP1469876B1 Antimicrobial cationic peptides and formulations thereof |
| 04/06/2011 | EP1467749B1 Thrombin derived peptides for promoting cardiac tissue repair |
| 04/06/2011 | EP1411979B1 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv |
| 04/06/2011 | EP1407030B1 Methods for large scale production of recombinant dna-derived tpa or k2s molecules |
| 04/06/2011 | EP1370277B1 Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis |
| 04/06/2011 | EP1255556B1 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 04/06/2011 | CN1910284B Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same |
| 04/06/2011 | CN1840177B Injection liquid of thymic peptide alpha 1 and preparation method thereof |
| 04/06/2011 | CN1658893B G-type peptides to ameliorate atherosclerosis |
| 04/06/2011 | CN1649612B Induction method for cell differentiation |
| 04/06/2011 | CN102007144A Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof |
| 04/06/2011 | CN102006882A Treating neurodegenerative diseases with progranulin (pgrn) |
| 04/06/2011 | CN102006881A Protein having pesticidal activity |
| 04/06/2011 | CN102006853A Topical composition for external use and process for producing the same |
| 04/06/2011 | CN102002106A Fusion protein MBP-NAP and preparation method and application thereof |
| 04/06/2011 | CN102002102A Body weight modulators, corresponding nucleic acids and proteins, and their use for diagnosis and therapy |
| 04/06/2011 | CN102002095A Microwave irradiation solid phase synthesis of balsam pear hypoglycemic MC-JJ0108 polypeptide analogue and application thereof |
| 04/06/2011 | CN102000325A Pramlintide buccal tablets and preparation method thereof |
| 04/06/2011 | CN102000324A Long-efficiency and stable animal interferon solution preparation and preparation method thereof |
| 04/06/2011 | CN102000323A Application of SJ16 protein in preparing immunosuppressive drugs |
| 04/06/2011 | CN102000322A Drug resisting against liver cancer, and preparation and application thereof |
| 04/06/2011 | CN102000321A Medicinal composition |